Exact Sciences Co. (NASDAQ:EXAS) Shares Sold by GTS Securities LLC

GTS Securities LLC reduced its stake in Exact Sciences Co. (NASDAQ:EXAS - Free Report) by 65.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 6,398 shares of the medical research company's stock after selling 12,128 shares during the period. GTS Securities LLC's holdings in Exact Sciences were worth $360,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Perigon Wealth Management LLC grew its position in shares of Exact Sciences by 3.2% in the 4th quarter. Perigon Wealth Management LLC now owns 8,436 shares of the medical research company's stock valued at $474,000 after buying an additional 264 shares during the last quarter. Robeco Institutional Asset Management B.V. boosted its stake in Exact Sciences by 37.5% in the fourth quarter. Robeco Institutional Asset Management B.V. now owns 37,286 shares of the medical research company's stock valued at $2,095,000 after acquiring an additional 10,165 shares in the last quarter. Forsta AP Fonden grew its holdings in shares of Exact Sciences by 1.3% during the fourth quarter. Forsta AP Fonden now owns 39,300 shares of the medical research company's stock worth $2,208,000 after purchasing an additional 500 shares during the last quarter. Swedbank AB grew its holdings in shares of Exact Sciences by 76.1% during the fourth quarter. Swedbank AB now owns 30,848 shares of the medical research company's stock worth $1,733,000 after purchasing an additional 13,333 shares during the last quarter. Finally, Baader Bank Aktiengesellschaft acquired a new stake in shares of Exact Sciences during the fourth quarter worth about $4,329,000. Institutional investors and hedge funds own 88.82% of the company's stock.

Wall Street Analyst Weigh In

EXAS has been the subject of a number of research analyst reports. Scotiabank upped their target price on Exact Sciences from $70.00 to $73.00 and gave the company a "sector outperform" rating in a research report on Monday, February 24th. William Blair reissued an "outperform" rating on shares of Exact Sciences in a report on Thursday, February 20th. Royal Bank of Canada lifted their target price on shares of Exact Sciences from $52.00 to $54.00 and gave the company a "sector perform" rating in a report on Friday, May 2nd. Robert W. Baird increased their price target on shares of Exact Sciences from $69.00 to $72.00 and gave the stock an "outperform" rating in a research note on Friday, May 2nd. Finally, Barclays lifted their price objective on shares of Exact Sciences from $55.00 to $75.00 and gave the company an "overweight" rating in a research note on Friday, May 2nd. Two analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $70.90.

Exact Sciences Price Performance

Shares of EXAS traded down $0.15 during trading hours on Monday, reaching $56.13. The company had a trading volume of 2,865,834 shares, compared to its average volume of 2,590,794. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. Exact Sciences Co. has a 12-month low of $39.97 and a 12-month high of $72.83. The firm has a 50 day simple moving average of $48.95 and a 200-day simple moving average of $52.09. The company has a market capitalization of $10.59 billion, a price-to-earnings ratio of -10.08 and a beta of 0.92.

Exact Sciences (NASDAQ:EXAS - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical research company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.16. Exact Sciences had a negative net margin of 37.29% and a negative return on equity of 5.29%. The company had revenue of $706.79 million during the quarter, compared to analysts' expectations of $688.58 million. During the same period last year, the company posted ($0.60) earnings per share. The firm's quarterly revenue was up 10.9% compared to the same quarter last year. Research analysts expect that Exact Sciences Co. will post -0.58 earnings per share for the current year.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.